financetom
Business
financetom
/
Business
/
Kellanova posts upbeat Q1 results as demand held steady
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kellanova posts upbeat Q1 results as demand held steady
May 2, 2024 6:09 AM

May 2 (Reuters) - Pop-Tarts maker Kellanova ( K ) beat

Wall Street estimates for first-quarter sales and profit on

Thursday, boosted by higher prices and firm demand for its

breakfast cereals and ready-to-eat snacks.

The Rice Krispies maker's shares were up nearly 2% in

premarket trading.

Kellanova ( K ), which rebranded itself late last year, is known

for its diverse portfolio of brands like Grahams Crackers,

Nutri-Grain breakfast bars and frozen food like Morningstar

Farms.

The company, like other major brands in the packaged food

industry, has ramped up prices, banking on the popularity of its

premium products among consumers, particularly in North America.

Despite price increases and sticky inflation, consumers

remain loyal to their favorite snack brands, shunning cheaper

alternatives.

Kellanova ( K ), also home to internationally recognized cereal

brands such as Frosties and Special K, said its prices rose by

8.5% in the quarter, while organic sales volumes fell 3.1%.

The strong results echo sentiments from packaged food peer

Conagra Brands ( CAG ) that posted upbeat quarterly results last

month, helped by a rebound in demand for its pantry staples and

frozen foods.

Kellanova's ( K ) snacking business, formerly known as Kellogg,

reported net sales of $3.20 billion in the three months ended

March 30, above analysts' expectations of $3.16 billion,

according to LSEG data.

Higher prices also helped drive its adjusted gross margin to

35.7% from 31.0% a year earlier.

The company, which spun-off its North American cereal

business into WK Kellogg last year, posted an adjusted profit of

$1.01 per share for the quarter, surpassing expectations of 85

cents per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FTC Seeking Info From JPMorgan, Mastercard on 'Surveillance Pricing'
FTC Seeking Info From JPMorgan, Mastercard on 'Surveillance Pricing'
Jul 23, 2024
09:48 AM EDT, 07/23/2024 (MT Newswires) -- The US Federal Trade Commission said Tuesday it issued orders to JPMorgan Chase ( JPM ) , Mastercard ( MA ) , Accenture ( ACN ) and five other companies that offer surveillance pricing products and services that incorporate data about consumers' characteristics and behavior. The orders seek information about the potential impact...
US, Canadian pot firms eye Germany for growth as market stagnates at home
US, Canadian pot firms eye Germany for growth as market stagnates at home
Jul 23, 2024
By Sourasis Bose (Reuters) - North American cannabis firms, facing prohibitive laws, an overcrowded market and a deeply entrenched illicit sector at home are ramping up investments in Germany after the country partly legalized marijuana use. Germany, the largest medical cannabis market in Europe, decriminalized cannabis possession and small-scale home cultivation in April, making it easier for doctors to prescribe...
Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment
Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment
Jul 23, 2024
09:48 AM EDT, 07/23/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Tuesday that it has submitted a supplemental new drug application to the US Food and Drug Administration for Zoryve foam 0.3% to treat adults and adolescents aged 12 and above with scalp and body psoriasis. The submission is backed by positive results from a late-stage trial, a...
Enlivex Therapeutics Gets Regulatory Nod in Israel to Begin Phase I Trial for Potential Psoriatic Arthritis Treatment
Enlivex Therapeutics Gets Regulatory Nod in Israel to Begin Phase I Trial for Potential Psoriatic Arthritis Treatment
Jul 23, 2024
09:53 AM EDT, 07/23/2024 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) said Tuesday it has received authorization from the Israeli Ministry of Health to start a phase I clinical trial to assess the safety and tolerability of Allocetra after injection into an affected joint in psoriatic arthritis patients. The company said measuring the frequency and severity of adverse events...
Copyright 2023-2026 - www.financetom.com All Rights Reserved